$URGN
UroGen Pharma Ltd.

2021 Q2 Form 10-Q Financial Statement

#000156459021040510 Filed on August 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $13.03M $372.0K $0.00
YoY Change 3403.23% 1966.67%
Cost Of Revenue $1.427M $48.00K $0.00
YoY Change 2872.92%
Gross Profit $11.61M $324.0K $0.00
YoY Change 3481.79% 1700.0%
Gross Profit Margin 89.05% 87.1%
Selling, General & Admin $22.30M $24.02M $21.97M
YoY Change -7.14% 74.36% 72.92%
% of Gross Profit 192.19% 7412.96%
Research & Development $12.12M $8.106M $16.59M
YoY Change 49.57% -18.91% 70.48%
% of Gross Profit 104.47% 2501.85%
Depreciation & Amortization $200.0K $100.0K $100.0K
YoY Change 100.0% 0.0% 0.0%
% of Gross Profit 1.72% 30.86%
Operating Expenses $34.43M $32.12M $38.56M
YoY Change 7.17% 35.14% 71.89%
Operating Profit -$22.82M -$31.80M -$38.56M
YoY Change -28.23% 33.88% 71.89%
Interest Expense $105.0K $520.0K $810.0K
YoY Change -79.81% -61.19% -19.8%
% of Operating Profit
Other Income/Expense, Net -$3.192M -$70.00K -$40.00K
YoY Change 4460.0% 0.0% 100.0%
Pretax Income -$25.91M -$31.35M -$37.79M
YoY Change -17.35% 39.45% 76.26%
Income Tax $312.0K
% Of Pretax Income
Net Earnings -$26.22M -$31.35M -$37.79M
YoY Change -16.35% 39.47% 76.24%
Net Earnings / Revenue -201.21% -8427.15%
Basic Earnings Per Share -$1.17
Diluted Earnings Per Share -$1.174M -$1.441M -$1.786M
COMMON SHARES
Basic Shares Outstanding 22.33M 21.15M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $121.0M $125.1M $119.1M
YoY Change -3.25% -33.87% -51.72%
Cash & Equivalents $64.55M $37.57M $27.69M
Short-Term Investments $57.71M $88.80M $92.60M
Other Short-Term Assets $6.533M $3.300M $2.800M
YoY Change 97.97% 65.0% 75.0%
Inventory $3.421M $1.125M
Prepaid Expenses
Receivables $9.512M $402.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $140.5M $129.9M $121.9M
YoY Change 8.16% -32.06% -50.91%
LONG-TERM ASSETS
Property, Plant & Equipment $2.001M $1.401M $991.0K
YoY Change 42.83% 54.13% 6.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $8.290M $26.50M $40.10M
YoY Change -68.72% -39.64%
Other Assets $1.103M $200.0K $500.0K
YoY Change 451.5% -92.18% -81.99%
Total Long-Term Assets $13.27M $31.20M $45.00M
YoY Change -57.47% -34.14% 1097.76%
TOTAL ASSETS
Total Short-Term Assets $140.5M $129.9M $121.9M
Total Long-Term Assets $13.27M $31.20M $45.00M
Total Assets $153.8M $161.1M $166.9M
YoY Change -4.55% -32.47% -33.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.830M $4.598M $4.152M
YoY Change 5.05% 118.85% 144.24%
Accrued Expenses $13.37M $11.80M $10.10M
YoY Change 13.34% 21.65% 17.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.06M $16.42M $14.20M
YoY Change 16.03% 38.66% 38.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $78.44M $2.000M $2.300M
YoY Change 3822.05% 5.26% 4.55%
Total Long-Term Liabilities $78.44M $2.000M $2.300M
YoY Change 3822.05% 2.93% 5.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.06M $16.42M $14.20M
Total Long-Term Liabilities $78.44M $2.000M $2.300M
Total Liabilities $97.50M $18.42M $16.48M
YoY Change 429.39% 33.58% 32.21%
SHAREHOLDERS EQUITY
Retained Earnings -$408.7M -$297.2M -$265.8M
YoY Change 37.52% 78.18% 84.18%
Common Stock $439.1M $416.0M
YoY Change 770178.95% 742673.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.27M $142.7M $150.5M
YoY Change
Total Liabilities & Shareholders Equity $153.8M $161.1M $166.9M
YoY Change -4.54% -32.48% -33.77%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$26.22M -$31.35M -$37.79M
YoY Change -16.35% 39.47% 76.24%
Depreciation, Depletion And Amortization $200.0K $100.0K $100.0K
YoY Change 100.0% 0.0% 0.0%
Cash From Operating Activities -$18.95M -$23.92M -$35.64M
YoY Change -20.79% 64.29% 98.7%
INVESTING ACTIVITIES
Capital Expenditures -$66.00K -$280.0K $96.00K
YoY Change -76.43% 600.0% 118.18%
Acquisitions
YoY Change
Other Investing Activities -$30.67M $17.80M $13.12M
YoY Change -272.3% -112.52%
Cash From Investing Activities -$30.74M $17.51M $13.03M
YoY Change -275.53% -112.31% -29702.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 72.52M 16.30M 90.00K
YoY Change 344.9% 4305.41% -99.94%
NET CHANGE
Cash From Operating Activities -18.95M -23.92M -35.64M
Cash From Investing Activities -30.74M 17.51M 13.03M
Cash From Financing Activities 72.52M 16.30M 90.00K
Net Change In Cash 22.84M 9.890M -22.52M
YoY Change 130.91% -106.32% -115.47%
FREE CASH FLOW
Cash From Operating Activities -$18.95M -$23.92M -$35.64M
Capital Expenditures -$66.00K -$280.0K $96.00K
Free Cash Flow -$18.88M -$23.64M -$35.73M
YoY Change -20.14% 62.81% 98.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
urgn:JelmytosMember
CY2020Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
urgn:JelmytosMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
urgn:JelmytosMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
urgn:JelmytosMember
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7047000
CY2021Q2 us-gaap Inventory Net
InventoryNet
3421000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1964000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5308000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3364000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
140498000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
115619000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2001000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2046000
CY2021Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
223000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
223000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1653000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2158000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
8290000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
1893000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1103000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
66000
CY2021Q2 us-gaap Assets
Assets
153768000
CY2020Q4 us-gaap Assets
Assets
122005000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10342000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10023000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6773000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9554000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1941000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1859000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19056000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21436000
CY2021Q2 urgn Prepaid Forward Obligation
PrepaidForwardObligation
74802000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
922000
CY2021Q2 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
2717000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20517000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
372000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
1427000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
48000
us-gaap Cost Of Revenue
CostOfRevenue
2324000
us-gaap Cost Of Revenue
CostOfRevenue
48000
CY2021Q2 us-gaap Gross Profit
GrossProfit
11605000
CY2020Q2 us-gaap Gross Profit
GrossProfit
324000
us-gaap Gross Profit
GrossProfit
18193000
us-gaap Gross Profit
GrossProfit
324000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12124000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8106000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22637000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24694000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22304000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24018000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
44493000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45991000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22823000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-31800000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48937000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70361000
CY2021Q2 urgn Financing On Prepaid Forward Obligations
FinancingOnPrepaidForwardObligations
3120000
urgn Financing On Prepaid Forward Obligations
FinancingOnPrepaidForwardObligations
3120000
CY2021Q2 urgn Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
33000
CY2020Q2 urgn Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
451000
urgn Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
212000
urgn Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
1219000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25910000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31349000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51845000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69142000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
312000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
312000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-31349000
us-gaap Net Income Loss
NetIncomeLoss
-52157000
us-gaap Net Income Loss
NetIncomeLoss
-69142000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26222000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-31349000
us-gaap Net Income Loss
NetIncomeLoss
-52157000
us-gaap Net Income Loss
NetIncomeLoss
-69142000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-98000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
449000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-226000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
484000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26320000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30900000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52383000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68658000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.44
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.22
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22331119
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21753001
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22287037
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21454341
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
76491000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6046000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-98000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
56271000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
150454000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
210000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7119000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15777000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
449000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-31349000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
142660000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
96355000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12241000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-226000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
56271000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
180302000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
503000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14736000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15777000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
484000
us-gaap Net Income Loss
NetIncomeLoss
-69142000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
142660000
us-gaap Net Income Loss
NetIncomeLoss
-52157000
us-gaap Net Income Loss
NetIncomeLoss
-69142000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
401000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
178000
urgn Accrued Financing On Prepaid Forward Obligation
AccruedFinancingOnPrepaidForwardObligation
2330000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-181000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-234000
us-gaap Share Based Compensation
ShareBasedCompensation
12241000
us-gaap Share Based Compensation
ShareBasedCompensation
14736000
urgn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
469000
urgn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
753000
urgn Operating Lease Liability Adjustments
OperatingLeaseLiabilityAdjustments
652000
urgn Operating Lease Liability Adjustments
OperatingLeaseLiabilityAdjustments
748000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1457000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1125000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2465000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
402000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1944000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1035000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1026000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
319000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2046000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2781000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-967000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
195000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46346000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59564000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
41655000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
29688000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
26295000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
60610000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
356000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
383000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15716000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30539000
urgn Proceeds From Prepaid Forward Arrangement
ProceedsFromPrepaidForwardArrangement
72472000
urgn Proceeds From Prepaid Forward Arrangement
ProceedsFromPrepaidForwardArrangement
503000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
58000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15885000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
11000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72519000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16388000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10457000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12637000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54090000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50211000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64547000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37574000
urgn Non Cash Purchase Of Property And Equipment
NonCashPurchaseOfPropertyAndEquipment
219000
urgn Non Cash New Lease Liabilities
NonCashNewLeaseLiabilities
-36000
urgn Non Cash New Lease Liabilities
NonCashNewLeaseLiabilities
29000
urgn Noncash Issuance Cost
NoncashIssuanceCost
32000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
90791000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
48000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
90836000
CY2021Q2 us-gaap Interest Receivable
InterestReceivable
200000
CY2021Q2 urgn Debt Securities Available For Sale Unrealized Gain Or Loss Position
DebtSecuritiesAvailableForSaleUnrealizedGainOrLossPosition
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 1 – Business and Nature of Operations</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Nature of Operations</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Ltd.<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>April<span style="letter-spacing:0.4pt;"> </span>20<span style="letter-spacing:-0.1pt;">0</span>4<span style="letter-spacing:0.45pt;"> </span>(“UPL”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Inc.,<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:0.15pt;"> wholly owned </span>subsidiary<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>UPL,<span style="letter-spacing:0.45pt;"> </span>was<span style="letter-spacing:0.35pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>Del<span style="letter-spacing:-0.1pt;">a</span>ware<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>October<span style="letter-spacing:0.65pt;"> </span>2015<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>began<span style="letter-spacing:0.5pt;"> </span>operati<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>February<span style="letter-spacing:0.75pt;"> </span>2016<span style="letter-spacing:0.45pt;"> </span>(“UPI”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPL<span style="letter-spacing:0.4pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>UPI<span style="letter-spacing:0.35pt;"> </span>(together<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>“Company”)<span style="letter-spacing:0.95pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.45pt;"> </span>bi<span style="letter-spacing:-0.1pt;">o</span>pharmaceutical<span style="letter-spacing:1.45pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>focused<span style="letter-spacing:0.65pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>deve<span style="letter-spacing:-0.1pt;">l</span>oping and commercializing<span style="letter-spacing:0.85pt;"> </span>novel<span style="letter-spacing:0.45pt;"> </span>therapies<span style="letter-spacing:0.75pt;"> </span>desi<span style="letter-spacing:-0.1pt;">g</span>ned<span style="letter-spacing:0.75pt;"> </span>to change<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>standard<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>care<span style="letter-spacing:0.4pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>urological<span style="letter-spacing:0.8pt;"> </span>pathologies. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s first commercial product, <span style="font-style:italic;">Jelmyto</span> (mitomycin) for pyelocalyceal solution, formerly known as UGN-101, and its product candidate UGN-102, and raising capital to support and expand these activities. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 15, 2020, the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <span style="font-style:italic;">Jelmyto</span>, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low grade-UTUC”). <span style="font-style:italic;">Jelmyto</span> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <span style="font-style:italic;">RTGel</span> technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:6pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p>
urgn Entity Incorporation Date Of Incorporation Month And Year
EntityIncorporationDateOfIncorporationMonthAndYear
2004-04
urgn Operations Commenced Date Month And Year
OperationsCommencedDateMonthAndYear
2016-02
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2 – Basis of Presentation</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (“SEC”) on March 18, 2021.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. Intercompany balances and transactions have been eliminated during consolidation.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has experienced net losses since its inception and has an accumulated deficit of $408.7 million and $356.5 million as of June 30, 2021 and December 31, 2020, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management’s cash flow projections the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next 12 months. The Company anticipates that it may need to raise additional capital in the future. There can be no assurances that the Company will be able to secure such additional financing if at all, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is not successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p>
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408700000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>preparation<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>conformity<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.35pt;"> U.S. </span>GAAP<span style="letter-spacing:0.5pt;"> </span>requires<span style="letter-spacing:0.65pt;"> </span>man<span style="letter-spacing:-0.1pt;">a</span>gement<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>make<span style="letter-spacing:0.45pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>affect the<span style="letter-spacing:0.05pt;"> </span>reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities,<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>disclosure<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>cont<span style="letter-spacing:-0.1pt;">i</span>ngent<span style="letter-spacing:0.85pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financ<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>the reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenue<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>expense<span style="letter-spacing:0.8pt;"> </span>duri<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>reporting<span style="letter-spacing:0.7pt;"> </span>period.<span style="letter-spacing:0.55pt;"> </span>Actual<span style="letter-spacing:0.5pt;"> </span>results<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>differ<span style="letter-spacing:0.45pt;"> </span>from<span style="letter-spacing:0.4pt;"> </span>those<span style="letter-spacing:0.45pt;"> </span>estimates.<span style="letter-spacing:0.8pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>applicable<span style="letter-spacing:0.9pt;"> </span>to the unaudited condensed<span style="letter-spacing:0.45pt;"> </span>consolidated<span style="letter-spacing:1pt;"> </span>financi<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:0.65pt;"> </span>statements,<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.3pt;"> critical </span>accounting<span style="letter-spacing:0.35pt;"> estimates relate </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>fair<span style="letter-spacing:0.3pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>compensat<span style="letter-spacing:-0.1pt;">i</span>on,<span style="letter-spacing:0.55pt;"> </span>measurement<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p>
CY2021Q2 urgn Accrued Selling General And Administrative Expense Current
AccruedSellingGeneralAndAdministrativeExpenseCurrent
1585000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4830000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3271000
CY2021Q2 urgn Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
129300000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company<span style="color:#000000;">’</span>s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">’</span>s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.</p>
CY2021Q2 urgn Accrued Sales Reserves
AccruedSalesReserves
712000
CY2020Q4 urgn Accrued Sales Reserves
AccruedSalesReserves
382000
CY2021Q2 urgn Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
1256000
CY2020Q4 urgn Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
1359000
CY2021Q2 urgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
859000
CY2020Q4 urgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1356000
CY2020Q4 urgn Accrued Selling General And Administrative Expense Current
AccruedSellingGeneralAndAdministrativeExpenseCurrent
2440000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1100000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1215000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10342000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10023000
us-gaap Investment Income Interest
InvestmentIncomeInterest
272000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1331000
urgn Other Finance Expenses Income
OtherFinanceExpensesIncome
-60000
urgn Other Finance Expenses Income
OtherFinanceExpensesIncome
-112000
urgn Finance Income Expense Net
FinanceIncomeExpenseNet
212000
urgn Finance Income Expense Net
FinanceIncomeExpenseNet
1219000
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2887000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1051000
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1560000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
913000
CY2021Q2 urgn Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
4447000
CY2020Q4 urgn Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
1964000
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
40200000
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
24
us-gaap Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
0
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
82546000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
88898000
CY2021Q2 urgn Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
8290000
CY2020Q4 urgn Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
1893000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
90836000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
90791000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3797000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3441000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1796000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1395000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2001000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2046000
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022
CY2021Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
urgn Lessee Operating Lease Extended Lease Expiration Date Month And Year
LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear
2022-08
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
260000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
428000
us-gaap Operating Lease Cost
OperatingLeaseCost
527000
us-gaap Operating Lease Cost
OperatingLeaseCost
858000
CY2021Q2 us-gaap Sublease Income
SubleaseIncome
56000
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
56000
us-gaap Sublease Income
SubleaseIncome
112000
us-gaap Sublease Income
SubleaseIncome
112000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
14000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
30000
us-gaap Variable Lease Cost
VariableLeaseCost
36000
us-gaap Variable Lease Cost
VariableLeaseCost
86000
CY2021Q2 us-gaap Lease Cost
LeaseCost
218000
CY2020Q2 us-gaap Lease Cost
LeaseCost
402000
us-gaap Lease Cost
LeaseCost
451000
us-gaap Lease Cost
LeaseCost
832000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1653000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2158000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
922000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1497000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1089000
us-gaap Operating Lease Payments
OperatingLeasePayments
2445000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
135000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M28D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0543
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1202000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2021Q2 urgn Lessee Operating Sub Lease Payments To Be Received Remainder Of Fiscal Year
LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear
117000
CY2021Q2 urgn Lessee Operating Sub Lease Payments To Be Received Next Twelve Months
LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths
243000
CY2021Q2 urgn Lessee Operating Sub Lease Payments To Be Received Two Years
LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears
251000
CY2021Q2 urgn Lessee Operating Sub Lease Payments To Be Received Three Years
LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears
49000
CY2021Q2 urgn Lessee Operating Sub Lease Payments To Be Received
LesseeOperatingSubLeasePaymentsToBeReceived
660000
CY2021Q2 urgn Lessee Operating Sub Lease Income From Fixed Lease Payments
LesseeOperatingSubLeaseIncomeFromFixedLeasePayments
56000
CY2020Q2 urgn Lessee Operating Sub Lease Income From Fixed Lease Payments
LesseeOperatingSubLeaseIncomeFromFixedLeasePayments
56000
urgn Lessee Operating Sub Lease Income From Fixed Lease Payments
LesseeOperatingSubLeaseIncomeFromFixedLeasePayments
112000
urgn Lessee Operating Sub Lease Income From Fixed Lease Payments
LesseeOperatingSubLeaseIncomeFromFixedLeasePayments
112000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13032000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
372000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20517000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
372000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M10D
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000.0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000.0
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22400000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22400000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22200000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22200000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6046000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7119000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12241000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14736000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
27700000
CY2021Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2700000
CY2021Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
700000

Files In Submission

Name View Source Status
0001564590-21-040510-index-headers.html Edgar Link pending
0001564590-21-040510-index.html Edgar Link pending
0001564590-21-040510.txt Edgar Link pending
0001564590-21-040510-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
urgn-10q_20210630.htm Edgar Link pending
urgn-10q_20210630_htm.xml Edgar Link completed
urgn-20210630.xsd Edgar Link pending
urgn-20210630_cal.xml Edgar Link unprocessable
urgn-20210630_def.xml Edgar Link unprocessable
urgn-20210630_lab.xml Edgar Link unprocessable
urgn-20210630_pre.xml Edgar Link unprocessable
urgn-ex311_8.htm Edgar Link pending
urgn-ex312_10.htm Edgar Link pending
urgn-ex321_7.htm Edgar Link pending
urgn-ex322_14.htm Edgar Link pending